• Corpus ID: 2158593

BIII-890-CL. Boehringer Ingelheim.

@article{Meythaler2002BIII890CLBI,
  title={BIII-890-CL. Boehringer Ingelheim.},
  author={Jay Meythaler},
  journal={Current opinion in investigational drugs},
  year={2002},
  volume={3 12},
  pages={
          1733-5
        }
}
  • Jay Meythaler
  • Published 1 December 2002
  • Medicine
  • Current opinion in investigational drugs
BIII-890-CL is a non-orally active sodium channel blocker under development by Boehringer Ingelheim Corp for the potential treatment of thromboembolic stroke. By April 2001, the compound was in phase II clinical trials for this indication, with trials ongoing in June 2002. The compound is also under investigation for its potential use in the treatment of pain. 
3 Citations
Reflections on Neuroprotection Research and the Path Toward Clinical Success
TLDR
From retrospective analysis in rt-PA ineligible stroke patients, embolectomy alone has proven safe and beneficial if completed within 6 h.
Voltage-gated cation channel modulators for the treatment of stroke
TLDR
There is a need for changes in clinical trial designs to optimise the selection of patients and the course of drug treatment to protect neurons during all periods of potential neuronal sensitivity to neuro-protectants, and the development of future solutions to these problems should result in an improved probability of success for the treatment of stroke.
Computational models of neuronal biophysics and the characterization of potential neuropharmacological targets.
TLDR
This brief review of neuromolecular medicine from the computational perspective provides compelling examples of how simulations can elucidate, explain, and predict the effect of chemical agonists, antagonists, and modulators in the nervous system.